Back to results
US 8,911,936 B2Granted
MicroRNA fingerprints during human megakaryocytopoiesis
AssigneeThe Ohio State University Research Foundation
InventorsCarlo M. Croce, Ramiro Garzon, George A. Calin
Life of this patent
Estimating the term…
Abstract
Described herein are methods of diagnosing a cancer and/or myeloproliferative disorder using microRNAs. Also described are compositions and methods related to cancers and myeloproliferative disorders.
Claims16
A method to identify a subject who has, or is at risk of developing a cancer and/or myeloproliferative disorder, comprising:
- i) obtaining a sample from a subject;
- ii) conducting a laboratory analysis of the sample so as to obtain physical data whether the sample contains an altered level of miR-130a;
- and
- iii) identifying the subject as one who has a cancer and/or a myeloproliferative disorder if the physical data indicate that the sample comprises an altered level of miR-130a;
- wherein the cancer and/or myeloproliferative disorder is selected from the group consisting of:
- acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL), and chronic myelogenous leukemia (CML).
3 more elements
A method to identify a subject who has, or is at risk of developing a cancer and/or myeloproliferative disorder, comprising:
- obtaining a sample from a subject;
- conducting a laboratory analysis of the sample so as to obtain physical data whether the sample contains altered levels of biomarkers, wherein the biomarkers comprise miR-130a and at least four additional biomarkers selected from the group consisting of:
- miR-10a, miR-126, miR-106, miR-10b, miR-124a, miR-032-prec, miR-101, miR-30c, miR-213, miR-132-prec, miR-150, miR-20, miR-339, let-7a, let-7d, miR-181c, miR-181b, and miR-17;
- and
- identifying the subject as one who has a cancer and/or a myeloproliferative disorder if the physical data indicate that the sample comprises a signature of altered levels of biomarkers, wherein the signature comprises miR-130a and at least four biomarkers selected from:
- miR-10a, miR-126, miR-106, miR-10b, miR-124a, miR-032-prec, miR-101, miR-30c, miR-213, miR-132-prec, miR-150, miR-20, miR-339, let-7a, let-7d, miR-181c, miR-181b, and miR-17;
- wherein the cancer and/or myeloproliferative disorder is selected from the group consisting of:
- acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL), and chronic myelogenous leukemia (CML).
5 more elements
A method to identify a subject who has, or is at risk of developing a cancer and/or myeloproliferative disorder, comprising:
- obtaining a sample from a subject;
- conducting a laboratory analysis of the sample so as to obtain physical data whether the sample contains altered levels of biomarkers, wherein the biomarkers are miR-130a and at least four biomarkers selected from the group consisting of:
- miR-10a, miR-101, miR-126, miR-99a, miR-33, miR-95, miR-10b, miR-155, let-7d, miR-99b-prec, miR-135-2-prec, miR-339, miR-99b, miR-106, let-7c, miR-148, miR-132-prec, and miR-20;
- and
- identifying the subject as one who has a cancer and/or a myeloproliferative disorder if the physical data indicate that the sample comprises a signature of altered levels of biomarkers, wherein the signature comprises miR-130a and at least four biomarkers selected from:
- miR-10a, miR-101, miR-126, miR-99a, miR-33, miR-95, miR-10b, miR-155, let-7d, miR-99b-prec, miR-135-2-prec, miR-339, miR-99b, miR-106, let-7c, miR-148, miR-132-prec, and miR-20;
- wherein the cancer and/or myeloproliferative disorder is selected from the group consisting of:
- acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL), and chronic myelogenous leukemia (CML).
5 more elements
Dependencies are inferred from the claim text.